Form 4: Revolution Medicines Executive Wei Lin Reports Stock Option Grant and RSU Holdings

Chief Medical Officer of Revolution Medicines, Wei Lin, reports the acquisition of stock options and disposal of common stock related to restricted stock units.

Summary

• Wei Lin, Chief Medical Officer of Revolution Medicines, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2025, Lin acquired 72,800 stock options with an exercise price of $40.74, vesting monthly over four years from the same date.
• Lin also disposed of 20,800 shares of common stock at $0, while still holding 91,651 shares, including 70,750 restricted stock units.
• The reported transactions reflect both the granting of new stock options and the vesting of previously awarded restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants and RSU vesting, which are standard compensation practices.

Positives

• The granting of stock options to the Chief Medical Officer aligns their interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the stock option grant suggests an expectation of future value creation.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, often vesting over a 3-4 year period.
• The size of the grant (72,800 shares) would need to be compared to grants at peer companies of similar market capitalization and stage of development to assess its relative magnitude.
• Companies like Amgen, Gilead, and Regeneron also use stock options extensively, but their executive compensation structures are significantly larger due to their scale.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• Employees may be indirectly impacted by the executive's performance and the overall success of the company.

Key Dates